HIV Pathogenesis, Vaccine, and Eradication Strategies: Second Edition

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue on “HIV Pathogenesis, Vaccine, and Eradication Strategies” (https://www.mdpi.com/journal/vaccines/special_issues/hiv_vaccine)”.

Human immunodeficiency virus (HIV) is still a very big problem for humanity. Fortunately, current anti-HIV drug regimens are highly effective in controlling HIV transmission and replication. However, it is well established that current anti-HIV therapy will not be able to eradicate or cure HIV. Numerous strategies have been applied unsuccessfully to flush out the latent HIV reservoirs, the main hurdle in HIV eradication. However, due to the mutadaptability of HIV, both preventive and therapeutic vaccines have been proven to be ineffective. In addition, several other prophylactic approaches, including microbicides, are struggling to make an impact.

We are interested in a broad area of research, focusing primarily on the mechanisms of HIV pathogenesis, life cycle, latency, and therapeutics. In addition, we are calling for manuscripts dealing with vaccine trials (preclinical and clinical) and strategies to develop a more effective HIV vaccine. We aim to present a combination of manuscripts dealing with different vital aspects of HIV, which can be exploited to develop a more effective anti-HIV therapy.

Dr. Mudit Tyagi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.